Predicting radiotherapy efficacy and prognosis in tongue squamous cell carcinoma through an in-depth analysis of a radiosensitivity gene signature

被引:0
作者
Lai, Jinzhi [1 ]
Yang, Hainan [2 ]
Chen, Junjun [3 ]
Chen, Shoubo [4 ]
Chen, Xiaofang [5 ]
机构
[1] Fujian Med Univ, Dept Oncol, Affiliated Hosp 2, Quanzhou, Fujian, Peoples R China
[2] Xiamen Univ, Dept Ultrasound, Affiliated Hosp 1, Xiamen, Fujian, Peoples R China
[3] Jiangxi Canc Hosp, Key Lab Personalized Diag & Treatment Nasopharynge, Natl Hlth Commiss NHC, Nanchang Med Coll, Nanchang, Jiangxi, Peoples R China
[4] Fujian Med Univ, Dept Orthopaed, Affiliated Hosp 2, Quanzhou, Fujian, Peoples R China
[5] Fujian Med Univ, Dept Otolaryngol, Affiliated Hosp 2, Quanzhou, Fujian, Peoples R China
来源
FRONTIERS IN ONCOLOGY | 2024年 / 14卷
关键词
tongue squamous cell carcinoma; radiosensitivity; radiotherapy; prognosis; prognostic index; INFILTRATING IMMUNE CELLS; RADIATION; SURVIVAL; DISCOVERY; HEAD;
D O I
10.3389/fonc.2024.1334747
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background Tongue squamous cell carcinoma (TSCC) is a prevalent tumor that affects many people worldwide. Radiotherapy is a common treatment option, but its efficacy varies greatly. This study seeks to validate the identified gene signature associated with radiosensitivity in TSCC, and its potential in predicting radiotherapy response and prognosis.Methods We analyzed 122 TSCC patients from TCGA database using the radiosensitivity signature and classified them into radiosensitive (RS) and radioresistant (RR) groups. Immune infiltration analysis methods were applied to investigate the immune status between different subgroups. Immunophenotype Score (IPS) and pRRophetic algorithm were employed to estimate the efficiency of treatment. A radioresistant TSCC cell line was established by gradually increasing radiation doses. Cell radiosensitivity was evaluated using the CCK-8 and colony formation assays. The expression of radiosensitivity-related genes was validated by qRT-PCR.Results Our study validated the predictive capacity of a previously identified "31-gene signature" in the TCGA-TSCC cohort, which effectively stratified patients into RS and RR groups. We observed that the RS group exhibited superior overall survival and progression-free survival rates relative to the RR group when treated with radiotherapy. The RS group was significantly enriched in most immune-related hallmark pathways, and may therefore benefit from immune checkpoint inhibitors. However, the RS group displayed lower sensitivity to first-line chemotherapy. A radioresistant TSCC cell line (CAL-27R) exhibited increased clonogenic potential and cell viability following irradiation, accompanied by downregulation of three radiosensitivity-related genes compared to its parental non-resistant cell (CAL-27). In addition, we constructed and validated a radiosensitivity-related prognostic index (PI) using 4 radiosensitivity-related genes associated with TSCC prognosis.Conclusion We assessed the ability of the radiosensitivity gene signature to predict outcomes in TSCC patients. our research provided valuable insights into the molecular pathways associated with radiosensitivity in TSCC and offered clinicians a practical tool to predict patient radiotherapy effectiveness and prognosis.
引用
收藏
页数:16
相关论文
共 50 条
  • [31] Gene regulation analysis of the effects of evodiamine on tongue squamous cell carcinoma
    Wu, Yuyan
    Wang, Jing
    Zhao, Jiayuan
    Zhang, Yunxia
    Sun, Yunjie
    Chen, Jian
    Wang, Jing
    JOURNAL OF CELLULAR BIOCHEMISTRY, 2019, 120 (09) : 15933 - 15940
  • [32] A novel metabolic-related gene signature for predicting clinical prognosis and immune microenvironment in head and neck squamous cell carcinoma
    Cao, Yongxin
    Dai, Zili
    Xie, Guofeng
    Liu, Guihong
    Guo, Liyi
    Zhang, Jian
    EXPERIMENTAL CELL RESEARCH, 2023, 428 (02)
  • [33] A Novel Immune-Related Seventeen-Gene Signature for Predicting Early Stage Lung Squamous Cell Carcinoma Prognosis
    Fan, Tao
    Lu, Zhiliang
    Liu, Yu
    Wang, Liyu
    Tian, He
    Zheng, Yujia
    Zheng, Bo
    Xue, Liyan
    Tan, Fengwei
    Xue, Qi
    Gao, Shugeng
    Li, Chunxiang
    He, Jie
    FRONTIERS IN IMMUNOLOGY, 2021, 12
  • [34] A novel 4-gene signature model simultaneously predicting malignant risk of oral potentially malignant disorders and oral squamous cell carcinoma prognosis
    Zhang, Xinyue
    Yang, Miao
    Liu, Yangfan
    Liu, Hailong
    Yang, Jin
    Luo, Jingjing
    Zhou, Hongmei
    ARCHIVES OF ORAL BIOLOGY, 2021, 129
  • [35] A three-long non-coding RNA signature that predicts tongue squamous cell carcinoma prognosis
    Li, Ran
    Li, Fanglong
    Wang, Yaozhong
    An, Pugen
    Hu, Yifan
    Xu, Jidong
    Zhao, Lu
    Lin, Xijiang
    ORAL DISEASES, 2023, 29 (02) : 557 - 562
  • [36] A 15-Gene Signature and Prognostic Nomogram for Predicting Overall Survival in Non-Distant Metastatic Oral Tongue Squamous Cell Carcinoma
    Liu, Muyuan
    Tong, Litian
    Liang, Bin
    Song, Xuhong
    Xie, Lingzhu
    Peng, Hanwei
    Huang, Dongyang
    FRONTIERS IN ONCOLOGY, 2021, 11
  • [37] Development and Validation of Autophagy-Related Gene Signature and Nomogram for Predicting Survival in Oral Squamous Cell Carcinoma
    Hou, Chen
    Cai, Hongshi
    Zhu, Yue
    Huang, Shuojin
    Song, Fan
    Hou, Jinsong
    FRONTIERS IN ONCOLOGY, 2020, 10
  • [38] Predicting the efficacy of radiotherapy for esophageal squamous cell carcinoma based on enhanced computed tomography radiomics and combined models
    Liu, Jihui
    Yang, Xiyue
    Mao, Xin
    Wang, Tingting
    Zheng, Xuhai
    Feng, Gang
    Dai, Tangzhi
    Du, Xiaobo
    FRONTIERS IN ONCOLOGY, 2023, 13
  • [39] Ferroptosis-related gene signature predicts the prognosis in Oral squamous cell carcinoma patients
    Li, Hongyu
    Zhang, Xiliu
    Yi, Chen
    He, Yi
    Chen, Xun
    Zhao, Wei
    Yu, Dongsheng
    BMC CANCER, 2021, 21 (01)
  • [40] Development and validation of a novel ferroptosis-related gene signature for predicting prognosis and immune microenvironment in head and neck squamous cell carcinoma
    He, Feinan
    Chen, Zhigang
    Deng, Wenting
    Zhan, Ting
    Huang, Xiaotong
    Zheng, Yiqing
    Yang, Haidi
    INTERNATIONAL IMMUNOPHARMACOLOGY, 2021, 98